WO2021199764A1 - 修飾ベクターの作製方法、及びベクターの修飾方法 - Google Patents

修飾ベクターの作製方法、及びベクターの修飾方法 Download PDF

Info

Publication number
WO2021199764A1
WO2021199764A1 PCT/JP2021/006113 JP2021006113W WO2021199764A1 WO 2021199764 A1 WO2021199764 A1 WO 2021199764A1 JP 2021006113 W JP2021006113 W JP 2021006113W WO 2021199764 A1 WO2021199764 A1 WO 2021199764A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
functional group
vector
binding
compound
Prior art date
Application number
PCT/JP2021/006113
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
博文 前田
隆英 佐々木
北野　光昭
Original Assignee
株式会社カネカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社カネカ filed Critical 株式会社カネカ
Priority to JP2022511650A priority Critical patent/JPWO2021199764A1/ja
Priority to US17/915,311 priority patent/US20230144068A1/en
Publication of WO2021199764A1 publication Critical patent/WO2021199764A1/ja

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Definitions

  • the present invention relates to a method for producing a modified vector and a method for modifying the vector.
  • Vectors are widely used for gene therapy, but there are problems such as insufficient transferability of vectors to target tissues. As a method for solving this problem, the proteins constituting the vector have been modified, but sufficient effects for showing the medicinal effect have not been obtained.
  • Non-Patent Document 1 a method of chemically modifying a vector and introducing a ligand for enhancing the function into the vector.
  • this method uses a reagent in which a site to be bound to a functional group on the vector and a ligand for enhancing the function are integrated, so that the available reagents are limited and it is said to be an effective method. hard.
  • Patent Document 1 As another method, a method of chemically modifying in two steps has been reported (Patent Document 1 and the like).
  • this method is a method using cysteine residues, and it is difficult to say that it is a simple method because it is necessary to release cysteine residues by a reduction treatment before chemical modification. Further, there is a possibility that the vector is decomposed by this reduction treatment.
  • Non-Patent Document 2 a method of modifying a vector to introduce a cysteine residue into a mutation and then chemically modifying the vector has been reported (Non-Patent Document 2 and the like), but since it takes time to introduce the mutation, it is a simple method. Is hard to say.
  • An object of the present invention is to solve the above-mentioned problems in the past and to achieve the following objects. That is, an object of the present invention is to provide a method for producing a modified vector and a method for modifying the vector, which can easily introduce various ligands without modifying or pretreating the vector.
  • the present inventors have added a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound to the functional group in the vector.
  • a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound to the functional group in the vector In the linker compound having, and in the ligand compound having the functional group (B) capable of binding to the functional group (B) to the functional group (B).
  • the present invention is based on the above-mentioned findings by the present inventors, and the means for solving the above-mentioned problems are as follows. That is, ⁇ 1>
  • the functional group (A) in the linker compound having a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound is bonded to the functional group in the vector. It is characterized by including a step of binding the functional group (C) to the functional group (B) in a ligand compound having a functional group (C) capable of binding to the functional group (B). This is a method for producing a modified vector.
  • the functional group (A) in the linker compound having a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound is bonded to the functional group in the vector. It is characterized by including a step of binding the functional group (C) to the functional group (B) in a ligand compound having a functional group (C) capable of binding to the functional group (B). This is a vector modification method.
  • a method for producing a modified vector which can solve the above-mentioned problems in the past, achieve the above-mentioned object, and easily introduce various ligands without modifying or pretreating the vector.
  • a method of modifying the vector can be provided.
  • FIG. 1 is a diagram showing the results of SDS-PAGE after the first step in Example 1.
  • FIG. 2 is a diagram showing the results of SDS-PAGE after the second step in Example 1.
  • FIG. 3 is a diagram showing the results of SDS-PAGE after the first step and after the second step in Examples 2 and 3.
  • FIG. 4 is a diagram showing the results of SDS-PAGE after the first step and after the second step in Example 4.
  • FIG. 5 is a diagram showing a purification chart of cation exchange chromatography after the first step in Example 4.
  • FIG. 6 is a diagram showing a purification chart of cation exchange chromatography after the second step in Example 4.
  • the method for producing the modified vector is a method for producing the functional group in a linker compound having a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound as the functional group in the vector.
  • the functional group (C) in the ligand compound having the functional group (C) capable of binding to the functional group (B) is bound to the functional group (B). It may include a second step and further have other steps.
  • first step and the second step are performed is not particularly limited and may be appropriately selected depending on the intended purpose, but various ligands capable of binding to the linker compound are simply introduced into the vector. It is preferable to perform the second step after the first step from the viewpoint that the ligand options can be expanded.
  • A) is a step of combining.
  • the vector is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a viral vector, a plasmid vector, an artificial chromosome vector, a cosmid vector, and a phosmid vector. Among these, viral vectors are preferable because they are widely used in gene therapy.
  • the virus used as the virus vector is not particularly limited and may be appropriately selected depending on the intended purpose.
  • adeno-associated virus AAV
  • adenovirus adenovirus
  • retrovirus adenovirus
  • lentivirus lentivirus
  • herpesvirus poliovirus
  • papilloma examples include viruses, vaccinia viruses, and pox viruses.
  • viruses vaccinia viruses, and pox viruses.
  • AAV adeno-associated virus
  • the serum types of AAV used as the virus vector include AAV1 (type 1 AAV), AAV2 (type 2 AAV), AAV3 (type 3 AAV), AAV4 (type 4 AAV), AAV5 (type 5 AAV), and AAV6 (6).
  • Type AAV AAV7 (7 type AAV), AAV8 (8 type AAV), AAV9 (9 type AAV), AAV10 (10 type AAV), AAV11 (11 type AAV), AAV12 (12 type AAV), AAV13 (13 type) AAV), AAV14 (14-type AAV), variants thereof, and the like can be mentioned, but there are no particular restrictions, and they can be appropriately selected depending on the intended purpose.
  • the variant is not particularly limited and may be appropriately selected depending on the intended purpose. For example, in order to improve the tissue specificity (directivity of infected cells) of the target cell, the variant is genetically modified (wild-type AAV). ) Modified AAV and the like.
  • the functional group in the vector is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include an amino group, a guanidine group, a hydroxyl group, a carboxyl group and an indole group. Among these, an amino group is preferable.
  • the functional group in the vector may be a functional group at a lysine residue, an arginine residue, a tyrosine residue, a serine residue, a threonine residue, or a tryptophan residue, and among these, the functional group at the lysine residue is preferable.
  • AAV adeno-associated virus
  • the functional group in the vector is a functional group constituting the capsid of the adeno-associated virus.
  • the capsid is composed of VP1, VP2, VP3 and the like.
  • the linker compound has a functional group (A) capable of binding to a functional group in the vector, a functional group (B) capable of binding to a ligand compound, and can further have a linking portion (D).
  • the functional group (A) that can be bonded to the functional group in the vector is not particularly limited and may be appropriately selected depending on the intended purpose.
  • OSO2R'or OP (O) (OR') 2 R'represents an alkyl group having 1 to 6 carbon atoms; an aryl group having 4 to 10 carbon atoms, and here 1 to 1 to 10 carbon atoms.
  • R' represents an alkyl group having 1 to 6 carbon atoms; an aryl group having 4 to 10 carbon atoms, and here 1 to 1 to 10 carbon atoms.
  • alkyl group of 6 a linear or branched alkyl group, particularly a methyl group; an ethyl group; (n-, i-) propyl group; (n-, i-, t-) butyl group is a preferable example.
  • aryl group having 4 to 10 carbon atoms examples include a phenyl group; a (2-, 3-, 4-) tolyl group; a (1-, 2-) naphthyl group; a 2-pyrrolyl group; a 2-furyl group.
  • Group; 3-thienyl group refers to an aromatic hydrocarbon group or heterocyclic group consisting of a 5- or 6-membered monocyclic or fused ring of 2-pyridyl group, and examples thereof include a methanesulfonyl group and a toluenesulfonyl group.
  • a succinimidyl group is preferable in terms of reactivity.
  • the functional group (A) may be one or more per molecule of the linker compound.
  • the functional group (B) that can bind to the ligand compound is not particularly limited and may be appropriately selected depending on the intended purpose.
  • an alkynyl group or an azide group is preferable, and an alkynyl group is more preferable, in terms of reactivity.
  • the number of functional groups (B) may be one or more per molecule of the linker compound.
  • the plurality of cases are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include an azide group and an alkynyl group.
  • the linking portion (D) can link the functional group (A) and the functional group (B), and does not react with the functional group (A), the functional group (B), and the ligand compound. As long as there is no particular limitation, it can be appropriately selected according to the purpose.
  • the connecting portion (D) may have a linear structure or a branched structure, but the linear structure is preferable.
  • the connecting portion (D) may be hydrophilic, hydrophobic, or amphipathic, but the hydrophilicity is preferable.
  • the length of the connecting portion (D) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, the length of the connecting portion (D) can be adjusted by the number of carbon atoms constituting the connecting portion (D).
  • the chemical structure of the connecting portion (D) is not particularly limited and may be appropriately selected depending on the intended purpose.
  • a structure having an alkylene group, a structure having a carbonyl group, a structure having an ether bond, and a carboxylic acid examples thereof include a structure having an ester bond and a combination thereof.
  • the structure having an ether bond may be chain-like (for example, a straight chain such as ethylene glycol, for example, a branched chain such as propylene glycol), or a structure containing cyclic (tetrahydropyran, tetrahydrofuran, 1,4-dioxane, etc.). ) May be.
  • the connecting portion (D) include an alkylene group, an alkyleneoxy group, a poly (alkyleneoxy) group, and the like.
  • the alkylene group is not particularly limited and may be appropriately selected depending on the intended purpose. For example, an alkylene group having 1 to 20 carbon atoms is preferable, an alkylene group having 1 to 10 carbon atoms is more preferable, and an alkylene group having 1 to 10 carbon atoms is more preferable. 1 to 4 alkylene groups are more preferred.
  • the alkyleneoxy group is not particularly limited and may be appropriately selected depending on the intended purpose. For example, an alkyleneoxy group having 1 to 100 carbon atoms is preferable, and an alkyleneoxy group having 4 to 100 carbon atoms is more preferable.
  • An alkyleneoxy group having 5 to 50 carbon atoms is more preferable.
  • the poly (alkyleneoxy) group is not particularly limited and may be appropriately selected depending on the intended purpose. For example, a poly (alkyleneoxy) group having 1 to 100 carbon atoms is preferable and the poly (alkyleneoxy) group has 5 to 50 carbon atoms. A poly (alkyleneoxy) group is more preferable, and a poly (alkyleneoxy) group having 6 to 40 carbon atoms is further preferable.
  • the alkylene oxide unit in the poly (alkyleneoxy) group is not particularly limited and may be appropriately selected depending on the intended purpose. For example, ethylene oxide and propylene oxide are preferable, and ethylene oxide is more preferable.
  • linker compound is not particularly limited and may be appropriately selected depending on the intended purpose.
  • the bond of the functional group (A) to a functional group in the vector is not particularly limited and may be appropriately selected depending on the intended purpose.
  • a solution containing the linker compound and the vector is mixed and reacted. Examples thereof include a method of mixing and reacting a solution containing the linker compound to which the ligand compound is bound and the vector. After these methods, a glycine solution may be added for further reaction.
  • the solvent of the solution may be an aqueous solvent or an organic solvent, or a mixed solvent of an aqueous solvent and an organic solvent.
  • the aqueous solvent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include HEPES (4- (2-hydroxyethyl) -1-piperazinethesulfonic acid) buffer, phosphoric acid buffer, distilled water and the like. Be done.
  • the pH of the HEPES buffer or the phosphate buffer is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably pH 4 or more and pH 12 or less, more preferably pH 5 or more and pH 11 or less, and pH 6 or more and pH 10 or less. More preferably, pH 7 or more and pH 9 or less are particularly preferable.
  • the organic solvent is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably compatible with water.
  • examples thereof include nitrile solvents such as acetonitrile, alcoholic solvents such as methanol, ethanol and propanol, ether solvents such as tetrahydrofuran and 1,4-dioxane, sulfur solvents such as dimethyl sulfoxide, and amide solvents such as dimethylformamide.
  • nitrile solvents such as acetonitrile
  • alcoholic solvents such as methanol, ethanol and propanol
  • ether solvents such as tetrahydrofuran and 1,4-dioxane
  • sulfur solvents such as dimethyl sulfoxide
  • amide solvents such as dimethylformamide.
  • the final concentration of the linker compound (before the addition of the glycine solution) is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 0.1 ⁇ M or more and 200 mM or less, and more preferably 0.5 ⁇ M or more and 100 mM or less. It is more preferably 5 ⁇ M or more and 80 mM or less, and particularly preferably 10 ⁇ M or more and 50 mM or less.
  • the titer of the vector is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 1 ⁇ 10 4 vg / ⁇ L or more and 1 ⁇ 10 100 vg / ⁇ L or less, and 1 ⁇ 10 5 vg / ⁇ L. It is more preferably ⁇ L or more and 5 ⁇ 10 80 vg / ⁇ L or less, and further preferably 1 ⁇ 10 6 vg / ⁇ L or more and 1 ⁇ 10 50 vg / ⁇ L or less.
  • the concentration of the glycine solution is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 0.1 ⁇ MM or more and 20 M or less, more preferably 0.5 ⁇ M or more and 10 M or less, and further preferably 5 ⁇ M or more and 5 M or less. It is preferable, and 10 ⁇ M or more and 4 M or less are particularly preferable.
  • the temperature of the reaction is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 0 ° C. or higher and 70 ° C. or lower, and more preferably 40 ° C. or lower.
  • the reaction time before the addition of the glycine solution is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 5 minutes or more and 120 hours or less, more preferably 30 minutes or more and 96 hours or less, and 1 hour. More preferably, it is 72 hours or less.
  • the reaction time after the addition of the glycine solution is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 5 minutes or more and 120 hours or less, more preferably 30 minutes or more and 96 hours or less, and 1 hour. More preferably, it is 72 hours or less.
  • the second step is a step of binding the functional group (C) to the functional group (B) in a ligand compound having a functional group (C) capable of binding to the functional group (B).
  • the ligand compound may have a functional group (C) capable of binding to the functional group (B), a ligand portion, and further a linking portion (E).
  • the linking portion (E) is not particularly limited as long as the functional group (C) can be linked to the ligand portion and does not react with the linker compound, the functional group (C), and the ligand portion. It can be appropriately selected according to the purpose.
  • the structure and specific examples of the connecting portion (E) are the same as those of the connecting portion (D) in the above-mentioned linker compound.
  • the ligand portion of the ligand compound is a substance that has an affinity for tissues, cells, proteins, etc.
  • the labeling means adding functions such as membrane permeability and target cell specificity to the vector, and adding the functions means modifying.
  • the introduction of the linker is also modified in that it adds a scaffolding function that facilitates the introduction of other functional substances.
  • the ligand portion is not particularly limited and may be appropriately selected depending on the intended purpose.
  • examples thereof include sugar compounds, peptides, low molecular weight compounds and immunoglobulins. These may be one or a plurality per molecule of the ligand compound. In the case of a plurality of cases, there is no particular limitation and it can be appropriately selected depending on the intended purpose, and examples thereof include sugar compounds and peptides.
  • the sugar compound is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include monosaccharides, oligosaccharides and polysaccharides.
  • the monosaccharides referred to herein have asymmetric carbons that are mirror images of the opposite sex. It may be a body, and oligosaccharides are composed of 2 to 6 molecules of monosaccharides, and polysaccharides are polymers in which monosaccharides are connected in a straight line or by branching, and monosaccharides, disaccharides, and trisaccharides are available due to availability. Is preferable.
  • the sugar compound is not particularly limited and may be appropriately selected depending on the intended purpose.
  • the protecting group is a substituent that protects a hydroxyl group or an amino group contained in a sugar compound, and can be appropriately selected depending on the intended purpose.
  • the protecting group for a hydroxyl group is an acyl group, a carbonate group or a carbamate group. , Cyclic acetal group, ether group and the like.
  • the acyl group is not particularly limited and may be appropriately selected depending on the intended purpose. For example, an acetyl group, a phenylacetyl group, a halogenated acetyl group, a methoxyacetyl group, a phenoxyacetyl group, a pivaloyl group, a benzoyl group and the like can be selected.
  • the carbonate group is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a t-butyl carbonate group and a benzyl carbonate group.
  • the carbamate group is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a phenyl carbamate group.
  • the cyclic acetal group is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a methylene acetal group, an ethylidene acetal group, an acetonide group and a benzylidene acetal group.
  • the ether group is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a benzyl ether group.
  • examples of the amino group protecting group include an acyl group and a carbamate group.
  • the acyl group is not particularly limited and may be appropriately selected depending on the intended purpose.
  • an acetyl group, a phenylacetyl group, a halogenated acetyl group, a methoxyacetyl group, a phenoxyacetyl group, a pivaloyl group, a benzoyl group and the like can be selected.
  • the carbamate group is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include 9-fluorenylmethyl carbamate group, phenyl carbamate group and t-butyl carbamate group.
  • the acetyl group is preferable because of its low toxicity and availability.
  • the peptide compound is not particularly limited and may be appropriately selected depending on the intended purpose.
  • LRVRRASHLRKLRKRLLRDAKKKKKKKKKKKKKKKKKKK (SEQ ID NO: 1), KKKKKKKKKKKKKKKLRRVRLARKKKKKKKKKLRRVRLARKKKKKKKKKLRRVRLLAR ), RQIKIWFQNRRMKWK (SEQ ID NO: 5), GWTLNSAGYLLGKINLKALAALKKIL (SEQ ID NO: 6), GALLFLGFLGAGSTMGASTGMGAWSQPKKKKRKV (SEQ ID NO: 7), RRRRRRHRRR (SEQ ID NO: 8) , LLIILRRRIRKQAHAHSK (SEQ ID NO: 12), KLALKLALKALKAALKA (SEQ ID NO: 13), LLIILRRRIRKQAHAHSK (SEQ ID NO: 14), GWTLNSAGYLLGKINLKALAALKKIL (SEQ ID NO: 15) It may be a
  • the low molecular weight compound is not particularly limited and may be appropriately selected depending on the intended purpose.
  • it may be a substance exhibiting a medicinal effect in vivo, such as paclitaxel and a low molecular weight antibody. Can be mentioned.
  • It may be a substance for evaluating the affinity with a substance in a living body, and examples thereof include biotin and dyes. Further, a polyellene glycol group may be added thereto.
  • the dye is not particularly limited, and is, for example, Fluoresane, HiLyte Fluor 555, HiLyte Fluor 647, HiLyte Fluor 750, DyLight 350, DyLight 405, DyLight 550, DyLightAleFlaze 633, DyLightAlZ Fluor 488, Fluoro 532, Fluoro 543, Fluoro 546, Fluoro 555, Fluoro 568, Fluoro 594, Fluoro 594, Fluoro 647, Fluoro 647, Fluoro, Fluoro A polyellene glycol group may be added thereto.
  • the immunoglobulin is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include IgG, IgM, IgA, IgD and IgE.
  • the upper limit of the weight average molecular weight of the ligand compound is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 500,000 or less, more preferably 300,000 or less, and more preferably 200,000 or less. More preferably, 100,000 or less is particularly preferable.
  • the lower limit of the weight average molecular weight of the ligand compound is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 200 or more.
  • ligand compound examples are not particularly limited and may be appropriately selected depending on the intended purpose.
  • 2-Azidoethyl 2-acetamido-2-deoxy- ⁇ -D-galactopyranose, 2-Azidoethyl ⁇ -D. -Glucopylanoside and the like can be mentioned.
  • the functional group (C) that can be bonded to the functional group (B) is not particularly limited and may be appropriately selected depending on the intended purpose.
  • an alkynyl group is preferable, an azido group is preferable when the functional group (B) is an alkynyl group, a tetrazine group or an alkenyl group is preferable when the functional group (B) is an alkenyl group, and the functional group (B).
  • the functional group (B) When is a carbonyl group, a hydrazine group or a hydroxylamine group is preferable, when the functional group (B) is a phosphine group, an azido group is preferable, and when the functional group (B) is a tetrazine group, an alkenyl group is preferable.
  • the functional group (B) is a hydrazine group, a carbonyl group is preferable, and when the functional group (B) is a hydroxylamine group, a carbonyl group is preferable.
  • the functional group (C) may be one or more per molecule of the ligand compound.
  • the plurality of cases are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include an azide group and an alkynyl group.
  • the bond of the functional group (C) to the functional group (B) is not particularly limited and may be appropriately selected depending on the intended purpose.
  • the functional group (A) to the functional group in the vector examples thereof include a method of mixing and reacting a solution containing the reactant obtained by binding and the ligand compound, a method of mixing and reacting a solution containing the linker compound and the ligand compound, and the like.
  • the solvent of the solution may be an aqueous solvent or an organic solvent, or a mixed solvent of an aqueous solvent and an organic solvent.
  • the aqueous solvent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include HEPES buffer, phosphoric acid buffer and distilled water.
  • the pH of the HEPES buffer or the phosphate buffer is not particularly limited and may be appropriately selected depending on the intended purpose. However, pH 1 or more and pH 12 or less are preferable, pH 2 or more and pH 12 or less are more preferable, and pH 3 or more and pH 11 or less are preferable. More preferably, pH 4 or more and pH 10 or less are particularly preferable.
  • the organic solvent is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably compatible with water.
  • nitrile solvents such as acetonitrile
  • alcoholic solvents such as methanol, ethanol and propanol
  • ether solvents such as tetrahydrofuran and 1,4 dioxane
  • sulfur solvents such as dimethyl sulfoxide
  • amide solvents such as dimethyl formamide.
  • the mixing ratio of the aqueous solvent and the organic solvent is not particularly limited, and any insoluble component may not be significantly generated.
  • the final concentration of the ligand compound is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 0.01 mM or more and 100 mM or less, more preferably 0.1 mM or more and 80 mM or less, and 0.2 mM or more and 50 mM. The following is more preferable.
  • the temperature of the reaction is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 0 ° C. or higher and 70 ° C. or lower, and more preferably 40 ° C. or lower.
  • the reaction time is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 5 minutes or more and 120 hours or less, more preferably 30 minutes or more and 96 hours or less, and 1 hour or more and 72 hours or less. More preferred.
  • the other steps are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a vector preparation step, a vector purification step, a reduction step, and a modification vector purification step.
  • the process for preparing the vector is not particularly limited and may be appropriately selected depending on the intended purpose.
  • a gene encoding the vector is transfected into cultured cells and the like from a cytolysate or a cell supernatant. Examples include a method of preparing a vector.
  • the process for purifying the vector is not particularly limited and may be appropriately selected depending on the intended purpose.
  • a method for purifying using a commercially available kit cell lysate for cation chromatography, and anion chromatography.
  • Size exclusion chromatography filters, methods of purification using ultrafiltration membranes, and the like.
  • the reducing step is not particularly limited and may be appropriately selected depending on the intended purpose. For example, after the step of binding the functional group (A) in the linker compound to the functional group in the vector, or After the step of adding a reducing agent such as DTT (dithiothreitol) to the reaction solution after the step of binding the functional group (C) of the Gand compound to the functional group (B), or after the purification step. Examples thereof include a step of adding a reducing agent such as DTT to the modified vector.
  • a reducing agent such as DTT
  • the purification step of the modified vector is not particularly limited and may be appropriately selected depending on the intended purpose.
  • the method for modifying the vector is a method of modifying the functional group (A) in a linker compound having a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound as the functional group in the vector.
  • the first step, the second step, and other steps in the method for modifying the vector are as described in the method for producing the modified vector.
  • ⁇ Reference example 1 Preparation of AAV2> PAAV2 and pRC-mi342 obtained by modifying HEK293T cells (ATCC) with a medium solution of PEI (Polysciences) and pAAV2 (CELL BioLABs, Inc) of the fluorescent protein GFP so as to express VENUS (GenBank: ACQ43955.1).
  • AAV2 was produced by transfecting a medium solution of (Takarabio) and pHelper (Takarabio) and culturing at 37 ° C. under 5% CO 2 for 4 days. After adding EDTA (Etylendiaminetetraacetic acid) and exfoliating the cells, the cells were centrifuged and the cell pellet and the centrifugal supernatant were collected.
  • EDTA Etylendiaminetetraacetic acid
  • ⁇ Reference example 2 Purification of AAV2> A vector was purified from the cell pellet obtained in Reference Example 1 using AAVpro® Purification Kit (AAV2) (TaKaRa 6232). The obtained purified AAV2 was titrated using RT-PCR (Quant Studio, SYBR Green method) and found to be 4 ⁇ 10 9 vg / ⁇ L.
  • the cell pellet obtained in Reference Example 1 was treated with Dulbecco's Phosphate-Buffered Saline containing 0.1 v / v% Triton X-100, a 1 M MgCl 2 aqueous solution, and an endonuclease. After stopping the reaction with EDTA, the supernatant was collected by centrifugation. The obtained supernatant was mixed and purified by cation chromatography (Thermo, POROS 50HS) and anion chromatography (Thermo, POROS 50HQ), and concentrated to obtain AAV2.
  • Example 1 Modification of AAV2>
  • the AAV2 solution obtained in Reference Example 2 was used.
  • reaction reagents 1A, 1B, 1C, 1D, 1E, 1F, 1G Using the HEPES buffer prepared by the above method, 0.125 mM DIBENZ [b, f] azocine-5 (6H) -hexanoic acid, 11,12-didehydro- ⁇ -oxo-, 2,5-dioxo-3.
  • Reaction reagent 1A which is a solution of -sulfo-1-pyrrolidinyl ester and sodium salt (Aldrich chemistry), was prepared.
  • reaction reagent 1B is 0.063 mM
  • reaction reagent 1C is 0.032 mM
  • reaction reagent 1D is 0.016 mM
  • reaction reagent 1E is 0.008 mM
  • reaction reagent 1F is 0. .004 mM
  • 0.002 mM DIBENZ [b, f] azocine-5 (6H) -hexanoic acid, 11,12-didehydro- ⁇ -oxo-, 2,5-dioxo-3-sulfo-1 which is a reaction reagent 1G -A pyrrolidinyl ester, sodium salt solution was prepared.
  • reaction reagent 2A which is a 16 mM 2-Azidoethyl 2-acetamido-2-deoxy- ⁇ -D-galactopyranoside (Sigma-Aldrich) solution was prepared. Further, the reaction reagent 2B is diluted 4 times, and the reaction reagent 2B is 4 mM, the reaction reagent 2C is 1 mM, and the reaction reagent 2D is 0.25 mM. Prepared.
  • (First step) 9 ⁇ L of the reaction reagents 1A, 1B, 1C, 1D, 1E, 1F and 1G prepared by the above method and 1 ⁇ L of the purified AAV2 solution were mixed and reacted in an incubator at 37 ° C. for 16 hours. Further, 2 ⁇ L of the 2M glycine solution (Wako) prepared in the above buffer is added and reacted in an incubator at 37 ° C. for 5 hours to generate the first step product 1A, the first step product 1B, and the first step product. A product 1C, a first step product 1D, a first step product 1E, a first step product 1F, and a first step product 1G were obtained.
  • lane 1 is a sample of the first step product 1A
  • lane 2 is a sample of the first step product 1B
  • lane 3 is a sample of the first step product 1C
  • lane 4 is a sample of the first step product 1D.
  • Lane 5 is a sample of the first step product 1E
  • lane 6 is a sample of the first step product 1F
  • lane 7 is a sample of the first step product 1G
  • lane 8 is a sample of unmodified AAV2
  • lane 9 is a sample of unmodified AAV2. It is a marker.
  • lane 1 is a sample of modified vector 2A
  • lane 2 is a sample of modified vector 2B
  • lane 3 is a sample of modified vector 2C
  • lane 4 is a sample of modified vector 2D
  • lane 5 is a buffer instead of reaction reagent 2.
  • the sample used, lane 6 is unmodified AAV2, and lane 7 is a marker.
  • Example 2 Modification of AAV2>
  • the purified AAV2 solution obtained in Reference Example 2 was used.
  • reaction reagent 1H 2 mM DIBENZ [b, f] azocine-5 (6H) -hexanoic acid, 11,12-didehydro- ⁇ -oxo-, 2,5-dioxo-3-sulfo using the phosphate buffer prepared by the above method.
  • a -1-pyrrolidinyl ester, sodium salt (Aldrich) solution (reaction reagent 1H) was prepared.
  • reaction reagent 3 Using the phosphate buffer prepared by the above method, a 16 mM 2-Azidoethyl ⁇ -D-Glucopylanoside (TCI) solution (reaction reagent 3) was prepared.
  • TCI 2-Azidoethyl ⁇ -D-Glucopylanoside
  • the modified vector 3A was obtained by reacting the reaction reagent 3 in the same manner as in Example 1. SDS-PAGE (ATTO E-R7.5L) was performed, and the progress of the reaction was confirmed by silver staining (Invitrogen). The results of silver staining are shown in FIG. It was found that the band of VP3 before the reaction was about 60 kDa and after the reaction was about 62 kDa, and the compound was added by 2 kDa.
  • Lane 1 of FIG. 3 is a sample of the first step product 1H of Example 2 (reaction reagent 1H), lane 2 is a sample of the modified vector 3A of Example 2 (reaction reagent 1H), and lane 5 is an unmodified AAV2.
  • the sample, lane 6, is a marker.
  • reaction reagent 4 Using the phosphate buffer prepared by the above method, 2 mM 4,7,10,13,16-Pentaoxa-20-azatricosanoic acid, 23- (11,12-didehydrodibenz [b, f] azocin-5 (6H)) -Yl) -19,23-dioxo-, 2,5-dioxo-1-pyrrolidinyl ester (BROADPHARM) solution (reaction reagent 4) was prepared.
  • the modified vector 3B was obtained by reacting the reaction reagent 3 in the same manner as in Example 1. SDS-PAGE (ATTO E-R7.5L) was performed, and the progress of the reaction was confirmed by silver staining (Invitrogen). The results of silver staining are shown in FIG. It was found that the band of VP3 before the reaction was about 64 kDa and after the reaction was about 68 kDa, and the compound was added by 4 kDa.
  • Lane 3 of FIG. 3 is a sample of the first step product 4 of Example 3 (reaction reagent 4), lane 4 is a sample of the modified vector 3B of Example 3 (reaction reagent 4), and lane 5 is an unmodified AAV2.
  • the sample, lane 6, is a marker.
  • Example 4 Modification of AAV2>
  • the AAV2 solution (6.6 ⁇ 10 9 vg / ⁇ L, 500 ⁇ L) obtained in Reference Example 3 was used.
  • reaction reagents 1I and 1J Preparation of reaction reagents 1I and 1J
  • a -1-pyrrolidinyl ester, sodium salt (Aldrich chemistry) solution was prepared and used as 1I. Further 1I was diluted to prepare 0.5 mM solution 1J.
  • reaction reagent 2E Preparation of reaction reagent 2E
  • a 2 mM 2-Azidoethyl 2-acetamido-2-deoxy- ⁇ -D-galactopyranoside (Sigma-Aldrich) solution was prepared and used as 2E.
  • Lanes 1 and 8 of FIG. 4 are unmodified AAV2
  • lane 2 is a sample of the first step product 1A of Example 4 (reaction reagent 1A: 0.125 mM)
  • lane 4 is Example 4 (reaction reagent 1J0. 5 mM) first step product 1J sample
  • lane 6 is a sample of first step product 1I of Example 4 (reaction reagent 1I: 1 mM)
  • lane 9 is a marker.
  • the first step product 1I, the first step product 1J, and the first step product 1A obtained by the reaction with the reaction reagents 1I, 1J, and 1A in Example 4 were subjected to cation exchange column chromatography (carrier: POROS 50HS). , Eluent: 20 mM phosphate buffer (pH 7.4), reagent condition: 100-370 mM NaCl aqueous solution). The results are shown in FIG. As a result of titration measurement using RT-PCR (Quant Studio, SYBR Green method) after purification, the first step product 1I was 5.8 ⁇ 10 11 vg / ⁇ L, and the first step product 1J was 1.8 ⁇ 10. 12 vg / ⁇ L, the first step product 1A was 1.2 ⁇ 10 12 vg / ⁇ L.
  • FIG. 5 shows unmodified AAV2
  • 2 is a sample of the first step product 1A of Example 4 (reaction reagent 1A: 0.125 mM)
  • 3 is a sample of Example 4 (reaction reagent 1J: 0.5 mM).
  • Sample of 1-step product 1J, 4 is a sample of 1-step product 1I of Example 4 (reaction reagent 1I: 1 mM)
  • the vertical axis of FIG. 5 shows the absorbance at 280 nm
  • the horizontal axis shows the elution volume.
  • Lanes 1 and 8 of FIG. 4 are unmodified AAV2, lane 3 is a sample of modified vector 2G of Example 4 (reaction reagent 1A: 0.125 mM and reaction reagent 2D: 0.25 mM), and lane 5 is Example 4.
  • Sample of modified vector 2F of (reaction reagent 1J: 0.5 mM and reaction reagent 2C: 1 mM)
  • lane 7 is a sample of modified vector 2E of Example 4 (reaction reagent 1I: 1 mM and reaction reagent 2E: 2 mM)
  • FIG. 6 shows unmodified AAV2
  • 2 is a sample of modified vector 2G of Example 4 (reaction reagent 1A: 0.125 mM and reaction reagent 2D: 0.25 mM)
  • 3 is Example 4 (reaction reagent 1J: 0).
  • It is a sample of the modified vector 2F of .5 mM and reaction reagent 2C: 1 mM)
  • the vertical axis of FIG. 6 shows the absorbance at 280 nm
  • the horizontal axis shows the elution volume.
  • Examples of aspects of the present invention include the following. ⁇ 1>
  • the functional group (A) in the linker compound having a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound is bonded to the functional group in the vector.
  • It is a method for producing a modification vector which comprises.
  • ⁇ 2> The production method according to ⁇ 1>, wherein the functional group in the vector is any one of an amino group, a guanidine group, a hydroxyl group, a carboxyl group, and an indole group.
  • ⁇ 3> Any of the above ⁇ 1> to ⁇ 2>, wherein the functional group in the vector is a functional group in a lysine residue, an arginine residue, a tyrosine residue, a serine residue, a threonine residue, and a tryptophan residue. It is a manufacturing method described in. ⁇ 4> The production method according to any one of ⁇ 1> to ⁇ 3>, wherein the functional group (A) is a succinimidyl group.
  • the functional group (B) is any one of an azido group, an alkynyl group, an alkenyl group, a carbonyl group, a phosphine group, a tetrazine group, a hydrazine group, and a hydroxylamine group, from ⁇ 1> to ⁇ 4>.
  • the production method according to any one of. ⁇ 6> The production method according to any one of ⁇ 1> to ⁇ 5>, wherein the weight average molecular weight of the ligand compound is 100,000 or less.
  • ⁇ 7> The production method according to any one of ⁇ 1> to ⁇ 6>, wherein the ligand compound is a sugar compound.
  • ⁇ 8> The production method according to ⁇ 7>, wherein the sugar compound has a polyethylene glycol group.
  • ⁇ 9> The production method according to any one of ⁇ 1> to ⁇ 6>, wherein the ligand compound is a peptide.
  • the linker compound has a polyethylene glycol group.
  • ⁇ 11> The production method according to any one of ⁇ 1> to ⁇ 10>, wherein the vector is an adeno-associated virus vector.
  • ⁇ 12> The production method according to ⁇ 11>, wherein the functional group in the vector is a functional group constituting the capsid of the adeno-associated virus vector.
  • the functional group in the vector is an amino group
  • the functional group (A) is a succinimidyl group
  • the functional group (B) or (C) is an azide group and / or an alkynyl group
  • the ligand compound is a sugar compound and / or a peptide.
  • the functional group in the vector is a functional group at a lysine residue
  • the functional group (B) or (C) is an azide group and / or an alkynyl group
  • the ligand compound is a sugar compound and / or a peptide.
  • the functional group (A) in the linker compound having a functional group (A) capable of binding to the functional group and a functional group (B) capable of binding to the ligand compound is bonded to the functional group in the vector. It is characterized by including a step of binding the functional group (C) to the functional group (B) in a ligand compound having a functional group (C) capable of binding to the functional group (B). This is a vector modification method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2021/006113 2020-03-31 2021-02-18 修飾ベクターの作製方法、及びベクターの修飾方法 WO2021199764A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022511650A JPWO2021199764A1 (ru) 2020-03-31 2021-02-18
US17/915,311 US20230144068A1 (en) 2020-03-31 2021-02-18 Method for preparing modified vector and method for modifying vector

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-062936 2020-03-31
JP2020062936 2020-03-31

Publications (1)

Publication Number Publication Date
WO2021199764A1 true WO2021199764A1 (ja) 2021-10-07

Family

ID=77928372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/006113 WO2021199764A1 (ja) 2020-03-31 2021-02-18 修飾ベクターの作製方法、及びベクターの修飾方法

Country Status (3)

Country Link
US (1) US20230144068A1 (ru)
JP (1) JPWO2021199764A1 (ru)
WO (1) WO2021199764A1 (ru)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523320A (ja) * 1999-09-29 2003-08-05 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
JP2003532368A (ja) * 1998-02-09 2003-11-05 ジェンザイム・コーポレイション 核酸デリバリービヒクル
JP2007514429A (ja) * 2003-12-18 2007-06-07 メディツィニシェ ホッホシューレ ハノーヴァー 細胞表面に連結され得る物質を連結するためのアダプター
JP2017522267A (ja) * 2014-05-19 2017-08-10 バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 癌ワクチン開発のための改変アデノウイルス
JP2019520853A (ja) * 2016-06-09 2019-07-25 セントレ・ナショナル・デ・ラ・レシェルシェ・サイエンティフィーク 化学修飾されたカプシドを有するｒａａｖ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532368A (ja) * 1998-02-09 2003-11-05 ジェンザイム・コーポレイション 核酸デリバリービヒクル
JP2003523320A (ja) * 1999-09-29 2003-08-05 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
JP2007514429A (ja) * 2003-12-18 2007-06-07 メディツィニシェ ホッホシューレ ハノーヴァー 細胞表面に連結され得る物質を連結するためのアダプター
JP2017522267A (ja) * 2014-05-19 2017-08-10 バロ セラピューティクス オイＶａｌｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 癌ワクチン開発のための改変アデノウイルス
JP2019520853A (ja) * 2016-06-09 2019-07-25 セントレ・ナショナル・デ・ラ・レシェルシェ・サイエンティフィーク 化学修飾されたカプシドを有するｒａａｖ

Also Published As

Publication number Publication date
JPWO2021199764A1 (ru) 2021-10-07
US20230144068A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
JP7100629B2 (ja) 化学修飾されたカプシドを有するｒａａｖ
EP2508603B1 (en) System for increasing gene expression, and vector supporting said system
Liu et al. Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides
CN104592364B (zh) 定点突变和定点修饰的腺相关病毒、其制备方法及应用
ES2761638T3 (es) Vectores lentivirales pseudotipados
EP2171456A2 (en) Self coupling recombinant antibody fusion proteins
TW201124428A (en) Method of dotecting cancer cells, method of structure analysis for sugar chain, and sugar chain derivatives
EP3212659B1 (en) Means and methods for site-specific functionalization of polypeptides
Wei et al. Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugs
US20230321144A1 (en) Modified immune cells for fibrosis and inflammation
CA3148210A1 (en) Multimeric protein domains for multifunctionality and enhanced secretion of therapeutic proteins
WO2021199764A1 (ja) 修飾ベクターの作製方法、及びベクターの修飾方法
WO2024149844A1 (en) Chemically-modified adeno-associated virus
Leray et al. Novel chemical tyrosine functionalization of adeno-associated virus improves gene transfer efficiency in liver and retina
Mulcrone et al. Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism
Garanina et al. Construction of recombinant adenovirus containing picorna-viral 2A-peptide sequence for the co-expression of neuro-protective growth factors in human umbilical cord blood cells
EP3577217A1 (en) RETARGETING OF VIRUSES OR VLPs
KR20240035940A (ko) 면역원성이 감소된 바이러스 벡터
EP3266870A1 (en) Conjugate and use thereof
JP2023050779A (ja) 修飾ベクターの作製方法、及びベクターの修飾方法
Jacinto et al. Screening polymeric ionic liquids for chromatography-based purification of bacteriophage M13
Lee et al. Multicistronic IVT mRNA for simultaneous expression of multiple fluorescent proteins
WO2023198652A1 (en) Chemically-modified adeno-associated viruses
WO2020026968A1 (ja) Ａａｖベクターによる遺伝子発現を増強する方法
Ludvigsen The human polyomavirus KI: A study on cell permissivity, sub-cellular localization of VP1 and presence in cerebrospinal fluid and urine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21781139

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022511650

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21781139

Country of ref document: EP

Kind code of ref document: A1